Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 70518-4362

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 70518-4362). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Rizatriptan Benzoate 10 mg orally disintegrating tablet packaging label shows quantity of 9 tablets. Label includes NDC 70518-4362-00, contains phenylalanine warning, and storage instructions. The product is round white F25 tablets, repackaged by RemedyRepack Inc., Indiana, PA.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose. The graph compares placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg using pooled data from four placebo-controlled outpatient studies. The x-axis represents hours post-dose, and the y-axis shows the estimated probability of response from 0% to 100%.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other migraine medications over 24 hours following the initial dose. The graph compares placebo, Rizatriptan Benzoate 5 mg tablets, and Rizatriptan Benzoate 10 mg tablets, with time in hours post-dose on the x-axis and probability of remediation or rescue on the y-axis.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
A line graph showing the estimated probability of achieving an initial headache response within 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg strengths compared to placebo. The x-axis represents hours post-dose and the y-axis represents the estimated probability of response, depicting greater response rates for the 10 mg and 5 mg doses over placebo.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)
A Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets (5 mg and 10 mg) or placebo for migraine rescue. The y-axis represents the estimated probability of remediation or rescue, and the x-axis shows hours post-dose, comparing responses among placebo and two dosages of Rizatriptan Benzoate OD tablets.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
A line graph comparing the observed percentage of patients reporting no headache pain up to 2 hours after dosing between Rizatriptan Benzoate orally disintegrating tablets and placebo. The x-axis represents hours post dose, and the y-axis shows percentage with 95% confidence intervals. Rizatriptan Benzoate shows a higher percentage of patients pain-free over time compared to placebo.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate depicting its molecular components including a triazole ring and a benzoate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.